Evidence map›Paper›PMID 24379661›Full record

ArticleInternational journal of nanomedicine2013

NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency.

Braydon L Burgess, Yumin He, Mandie M Baker, Bing Luo, Stephen F Carroll, Trudy M Forte, Michael N Oda

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Reconstituted HDL as a therapeutic delivery device.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2021
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Braydon L BurgessChildren's Hospital Oakland Research Institute, Oakland, CA, USA ; Lypro Biosciences, Berkeley, CA, USA.
Yumin HeChildren's Hospital Oakland Research Institute, Oakland, CA, USA.
Mandie M BakerChildren's Hospital Oakland Research Institute, Oakland, CA, USA ; Lypro Biosciences, Berkeley, CA, USA.
Bing LuoLypro Biosciences, Berkeley, CA, USA.
Stephen F CarrollLypro Biosciences, Berkeley, CA, USA.
Trudy M ForteLypro Biosciences, Berkeley, CA, USA.
Michael N OdaChildren's Hospital Oakland Research Institute, Oakland, CA, USA.
Lypro Biosciences (United States) · US

Funding

NanoDisk-Amphotericin B therapy for aspergillosisR44AI066444 · NIAID · LYPRO BIOSCIENCES, INC. · PI FORTE, TRUDY M · 2007 to 2011
$2.3M
NIAID NIH HHS 5R44AI066444-05NIAID NIH HHS R44 AI066444
6 · The paper itself

Abstract

objectivesNanoDisk-amphotericin B (ND-AMB) is a protein-phospholipid bioparticle containing a "super aggregate" form of antifungal AMB. While lipid-based formulations of AMB, including liposomal AMB (L-AMB), are safer than the deoxycholate (DOC) solubilized form (DOC-AMB), the potency of lipid-based formulations is attenuated. We have developed an AMB-based therapy that is both well tolerated and fully efficacious.

methodsPotency was determined using broth culture growth-inhibition assays and candidacidal kinetics by quantitative culture plating. Toxicology studies were performed in healthy mice. Efficacy was assessed using both immune-competent and leukopenic murine models of systemic Candida albicans infection.

resultsND-AMB C. albicans and Aspergillus fumigatus minimum inhibitory concentrations were fourfold and sixfold lower, respectively, than that observed for L-AMB. ND-AMB exhibited candidacidal activity at 0.125 mg/L, 16-fold lower than L-AMB. In mice, ND-AMB produced no statistically significant kidney or liver toxicity at 15 mg/kg, the highest dose tested. When evaluated in immune-competent mice infected with C. albicans, ND-AMB was at least as effective as DOC-AMB or L-AMB. In a leukopenic model of candidiasis, the 50% effective dose of ND-AMB was around threefold lower than L-AMB.

conclusionThese results indicate that ND-AMB exhibits a more favorable safety profile while maintaining uncompromised antifungal properties compared to both DOC-AMB and L-AMB. ND-AMB is a promising therapy for the treatment of invasive fungal infections.

Indexed as

Amphotericin BAnimalsAntifungal AgentsCandida albicansCandidiasisFemaleKaplan-Meier EstimateMiceMice, Inbred BALB CMicrobial Sensitivity TestsNanostructuresToxicity TestsAmphotericin BAntifungal Agentsapolipoprotein A-Icandidiasisdrug deliveryinfectious diseasesnanoparticles

Identifiers

PMID24379661
PMCPMC3867322
OpenAlexW1994810452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.